Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis (RA). A priority review voucher was submitted with the NDA, shortening the anticipated time for review.
The filing is supported by 52-week data from the global Phase 3 FINCH clinical program, which evaluated the efficacy and safety of filgotinib in 3,452 patients with moderate to severely active RA. In the FINCH studies, filgotinib met its primary endpoints and demonstrated durable efficacy and safety results across multiple RA patient populations, including in people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-naïve. Safety results were consistent across the trials and further reinforce the long-term safety and tolerability profile of filgotinib for a broad range of RA patients.
Despite the availability of current therapies, people living with RA may face persistent disease symptoms and inadequate responses to currently available therapies. One in five patients do not achieve complete disease remission during their lifetimes and remain in need of treatment options.
“The new drug application submission for filgotinib represents an important step forward in bringing a potential new treatment option to people living with RA,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “In clinical trials, filgotinib has demonstrated an efficacy and tolerability profile that may offer meaningful improvements in RA treatment response for patients with this chronic, debilitating disease.”
This filing is the third regulatory agency submission for filgotinib in the past five months following submissions to the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare earlier this year.
Filgotinib is an investigational agent and is not approved by any regulatory authority. Its efficacy and safety have not been established.
About the Filgotinib Collaboration i
Gilead and Galapagos NV are collaborative partners in the global development and commercialization of filgotinib in RA, and other potential inflammatory indications. In the United States, Gilead is solely responsible for the commercialization of filgotinib, pending approval of filgotinib by the FDA.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving filgotinib and the possibility that we may be unable to complete one or more of such trials in the currently anticipated timelines or at all. Further, it is possible that the parties may make a strategic decision to discontinue development of filgotinib, and as a result, filgotinib may never be successfully commercialized. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
__________________
i Gilead & Galapagos Filgotinib Clinical Program Trial Details: SELECTION (NCT02914522); DIVERSITY (NCT02914561); PENGUIN 1 (NCT04115748); PENGUIN 2 (NCT04115839)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005768/en/
Contact information
Greg Mann, Investors
(424) 322-1795
Arran Attridge, Media
(650) 425-8975
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Announces Proposed Offering of Senior Notes4.11.2025 16:15:00 EET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tende
Westlake Announces Cash Tender Offer4.11.2025 16:13:00 EET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of a cash tender offer to purchase (the “Offer”) any and all of the outstanding 3.600% Senior Notes due 2026 (the “Notes”) as set forth in the table below. The tender offer is being made solely pursuant to the terms and conditions set forth in an Offer to Purchase, dated November 4, 2025 (the “Offer to Purchase”). Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the tender offer. The tender offer is not conditioned on any minimum amount of the Notes being tendered. Subject to applicable law, Westlake may amend, extend or terminate the tender offer in its sole discretion. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Series of Notes CUSIP Numbers(1) Aggregate Principal Amount Outstanding U.S. Treasury Reference Security(2) Bloomberg Reference Page(2) Fixed Spread(3) 3.600% S
In-House Counsel Warn of Mounting Risks as Service of Process Volume Surges4.11.2025 16:00:00 EET | Press release
The volume of service of process (SOP)—the legal procedure by which one party formally notifies another of a legal action—is surging across the U.S., amplifying operational pressure and compliance risk for in-house legal teams. This is according to a new nationwide study commissioned by CSC, industry-leading registered agent and compliance service provider. CSC surveyed 250 senior in-house counsel across the U.S. and found that rising SOP volume and growing concerns around data accuracy are intensifying both risk and workload pressure.1 Respondents cited data accuracy as a significant challenge to SOP management (61%), followed by rising SOP volume (56%). More than three-quarters (76%) said their departments are spending “too much” or “excessive” time managing SOP, underscoring the growing operational demands placed on legal teams. The rising complexity of SOP, driven by new and differing state rules is increasing compliance exposure. Most respondents (59%) indicated that managing SOP
ITRS Named a Visionary in 2025 Gartner® Magic Quadrant™ for Digital Experience Monitoring for Second Consecutive Year4.11.2025 16:00:00 EET | Press release
ITRS today announced it has been named a Visionary in the 2025 Gartner® Magic Quadrant™ for Digital Experience Monitoring (DEM) for the second year in a row. ITRS is a pioneer in real-time monitoring and observability for mission-critical industries. Uptrends, its DEM solution, enables customers to deliver reliable, high-performing digital experiences across regulated and globally distributed environments. “We’re deeply committed to our clients’ success and proud to be named a Visionary for the second year in a row,” commented Ryan Terpstra, CEO of ITRS. “Digital Experience Monitoring connects IT system health to end-user satisfaction — empowering our clients to deliver world-class digital products that build loyalty, strengthen trust, and drive business growth.” Reducing Complexity, Enriching Observability: Agentic AI-Enabled DEM ITRS is infusing agentic AI into its DEM platform to enable customers to deploy holistic monitoring and adapt faster at enterprise scale. This minimizes the
Mobile Developers Enter a New Era of Platform Freedom With the Latest Updates to Xsolla Web Shop and Buy Button4.11.2025 16:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, announces new features and capabilities to the industry-leading web shop solution. Arriving as the U.S. market moves toward a new open era for external payments, new enhancements to the Xsolla Web Shop and Buy Button provide developers with the tools to drive higher margins and more player engagement across iOS and Android. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104283284/en/ (Graphic: Xsolla) The U.S. is now leading the push for more open app ecosystems, with similar moves in the UK, Europe, Japan, Brazil, and beyond to allow external payments. The Xsolla Web Shop enables studios to embrace this shift, increasing margins on every transaction as monetization options expand beyond app stores. Key benefits of the new plug-in features in Xsolla Web Shop include: Unlock higher margins via seamless purchases with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom